AR109503A1 - Composición farmacéutica que comprende (e)-2,4,6-trimetoxiestiril-3-[(carboximetil)amino]-4-metoxibencilsulfona, forma de dosificación oral y método de tratamiento - Google Patents
Composición farmacéutica que comprende (e)-2,4,6-trimetoxiestiril-3-[(carboximetil)amino]-4-metoxibencilsulfona, forma de dosificación oral y método de tratamientoInfo
- Publication number
- AR109503A1 AR109503A1 ARP170102376A ARP170102376A AR109503A1 AR 109503 A1 AR109503 A1 AR 109503A1 AR P170102376 A ARP170102376 A AR P170102376A AR P170102376 A ARP170102376 A AR P170102376A AR 109503 A1 AR109503 A1 AR 109503A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- amino
- trimetoxiestiril
- metoxibencilsulfona
- carboximethyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- HDPIOBZINCPGNV-JOBJLJCHSA-N 2-[5-[(e)-1-[(e)-1-[3-(carboxymethylamino)-4-methoxyphenyl]-3-(2,4,6-trimethoxyphenyl)prop-2-enyl]sulfonyl-3-(2,4,6-trimethoxyphenyl)prop-2-enyl]-2-methoxyanilino]acetic acid Chemical compound COC1=CC(OC)=CC(OC)=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=CC(OC)=CC=1OC)OC)C=1C=C(NCC(O)=O)C(OC)=CC=1)C1=CC=C(OC)C(NCC(O)=O)=C1 HDPIOBZINCPGNV-JOBJLJCHSA-N 0.000 abstract 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 abstract 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 abstract 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 abstract 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Reivindicación 1: Una composición farmacéutica, caracterizada porque comprende: a) (E)-2,4,6-trimetoxiestiril-3-[(carboximetil)amino]-4-metoxibencilsulfona, y sus sales farmacéuticamente aceptables; b) polietilenglicol básico pretratado de bajo peso molecular; c) pH sin diluir de alrededor de 11.0 a alrededor de 14.0; y d) menos de 5% de agua o disolución acuosa. Reivindicación 2: La composición farmacéutica de la reivindicación 1, caracterizada porque dicho polietilenglicol básico pretratado de bajo peso molecular comprende uno o más de PEG 200, PEG 300, PEG 400 y PEG 600.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762485355P | 2017-04-13 | 2017-04-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR109503A1 true AR109503A1 (es) | 2018-12-19 |
Family
ID=59856606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170102376A AR109503A1 (es) | 2017-04-13 | 2017-08-28 | Composición farmacéutica que comprende (e)-2,4,6-trimetoxiestiril-3-[(carboximetil)amino]-4-metoxibencilsulfona, forma de dosificación oral y método de tratamiento |
Country Status (19)
Country | Link |
---|---|
US (1) | US10098862B1 (es) |
EP (3) | EP3609471B1 (es) |
JP (1) | JP7202313B2 (es) |
KR (1) | KR102643626B1 (es) |
CN (2) | CN110536678A (es) |
AR (1) | AR109503A1 (es) |
AU (1) | AU2018253291B2 (es) |
BR (1) | BR112019021445A2 (es) |
CA (1) | CA3058664A1 (es) |
CL (1) | CL2019002899A1 (es) |
CO (1) | CO2019011299A2 (es) |
EA (1) | EA201992436A1 (es) |
ES (2) | ES2941538T3 (es) |
IL (2) | IL289806B2 (es) |
MX (1) | MX2022011860A (es) |
TW (2) | TWI809721B (es) |
UY (1) | UY37380A (es) |
WO (2) | WO2018190897A1 (es) |
ZA (2) | ZA201906671B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11382877B2 (en) | 2017-04-13 | 2022-07-12 | Onconova Therapeutics, Inc. | Formulation of (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100972131B1 (ko) | 2002-02-28 | 2010-07-26 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 증식성 질병 치료용 아미노-치환(e)-2,6-디알콕시스티릴 4-치환-벤질설폰 |
WO2006010152A2 (en) * | 2004-07-19 | 2006-01-26 | Onconova Therapeutics, Inc. | Formulations for parenteral administration of (e)-2,6-dialkoxystryryl 4-substituted benzylsulfones |
JP5278968B2 (ja) | 2006-08-30 | 2013-09-04 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 骨髄異形性症候群及び急性骨髄性白血病の治療のための組成物及び方法 |
EP2124569A4 (en) | 2007-01-16 | 2013-02-27 | Onconova Therapeutics Inc | FORMULATIONS FOR THE PARENTERAL ADMINISTRATION OF (E) -2,6-DIALKOXY STYRYL-4-SUBSTITUTED BENZYL SULPHONES |
CN104203235B (zh) | 2012-02-14 | 2018-11-23 | 赛多斯有限责任公司 | 苯达莫司汀的制剂 |
EP2928456B1 (en) * | 2012-12-07 | 2021-02-03 | Onconova Therapeutics, Inc. | Treatment of hematological cancer refractory to an anti-cancer agent |
-
2017
- 2017-08-28 AR ARP170102376A patent/AR109503A1/es unknown
- 2017-08-28 UY UY0001037380A patent/UY37380A/es unknown
- 2017-08-28 WO PCT/US2017/048890 patent/WO2018190897A1/en active Application Filing
- 2017-08-28 US US15/688,320 patent/US10098862B1/en active Active
-
2018
- 2018-04-13 CN CN201880024896.3A patent/CN110536678A/zh active Pending
- 2018-04-13 TW TW111105823A patent/TWI809721B/zh active
- 2018-04-13 KR KR1020197032006A patent/KR102643626B1/ko active IP Right Grant
- 2018-04-13 EP EP18718572.3A patent/EP3609471B1/en active Active
- 2018-04-13 IL IL289806A patent/IL289806B2/en unknown
- 2018-04-13 ES ES18718572T patent/ES2941538T3/es active Active
- 2018-04-13 EP EP20179085.4A patent/EP3733163B8/en active Active
- 2018-04-13 EP EP23150204.8A patent/EP4193988B1/en active Active
- 2018-04-13 CN CN202310430408.1A patent/CN116637095A/zh active Pending
- 2018-04-13 JP JP2019556217A patent/JP7202313B2/ja active Active
- 2018-04-13 WO PCT/US2018/027514 patent/WO2018191634A2/en active Search and Examination
- 2018-04-13 ES ES20179085T patent/ES2926042T3/es active Active
- 2018-04-13 IL IL269757A patent/IL269757B/en unknown
- 2018-04-13 EA EA201992436A patent/EA201992436A1/ru unknown
- 2018-04-13 CA CA3058664A patent/CA3058664A1/en active Pending
- 2018-04-13 TW TW107112770A patent/TWI759459B/zh active
- 2018-04-13 AU AU2018253291A patent/AU2018253291B2/en active Active
- 2018-04-13 BR BR112019021445A patent/BR112019021445A2/pt unknown
-
2019
- 2019-10-09 ZA ZA2019/06671A patent/ZA201906671B/en unknown
- 2019-10-11 CL CL2019002899A patent/CL2019002899A1/es unknown
- 2019-10-11 MX MX2022011860A patent/MX2022011860A/es unknown
- 2019-11-12 CO CONC2019/0011299A patent/CO2019011299A2/es unknown
-
2021
- 2021-10-08 ZA ZA2021/07580A patent/ZA202107580B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123023T1 (el) | Υδατικη φαρμακευτικη μορφοποιηση ταπενταδολης για χορηγηση απο το στομα | |
CL2020000122A1 (es) | Métodos de tratamiento para la fibrosis quística. | |
BR112018075140A2 (pt) | composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8 | |
AR107864A1 (es) | ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS | |
AR107014A1 (es) | Formulación farmacéutica acuosa | |
CY1121849T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου | |
CL2017003320A1 (es) | Formulaciones farmacéuticas que contienen tenofovir y emtricitabina | |
CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
CY1125033T1 (el) | Σκευασμα μεθοτρεξατης | |
CY1121345T1 (el) | Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης | |
AR100453A1 (es) | Composiciones para el cuidado oral que contienen polietilenglicol para estabilidad física | |
CY1123728T1 (el) | (2r,4r)-5-(5'-χλωρο-2'-φθοροδιφαινυλ-4-υλ) -2-υδροξυ-4- [(5-μεθυλοξαζολο-2-καρβονυλ) αμινο] πεντανοϊκο οξυ | |
AR100505A1 (es) | Composiciones dentífricas que mitigan la placa dental o tienen mejor captación de fluoruro | |
CR20160483A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
AR109168A1 (es) | Sales de derivados de 2,6-dimetilpirimidona y sus usos | |
PE20180039A1 (es) | Piroglutamato de vortioxetina | |
EA201790223A1 (ru) | Водный препарат, содержащий парацетамол и ибупрофен | |
TR201819662T4 (tr) | Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi. | |
CY1124609T1 (el) | Υγρη συνθεση ανθρωπινου ινωδογονου | |
BR112018068960A2 (pt) | formulações de enalapril | |
AR109503A1 (es) | Composición farmacéutica que comprende (e)-2,4,6-trimetoxiestiril-3-[(carboximetil)amino]-4-metoxibencilsulfona, forma de dosificación oral y método de tratamiento | |
EA201792121A1 (ru) | Фармацевтические солевые формы ингибитора семикарбазидчувствительной аминоксидазы (ssao) | |
EA202090164A1 (ru) | Изотретиноиновые перорально-слизистые композиции и способы их применения | |
EA201791191A1 (ru) | Водные фармацевтические композиции для местного применения в ротовой полости, содержащие флурбипрофен и декспантенол |